New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines
Primary Cutaneous Lymphomas Version 2.2020 Featured Updates to the NCCN Guidelines JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK Mehta-Shah, N., Horwitz, S. M., Ansell, S., Ai, W. Z., Barnes, J., Berta, S. K., Clemens, M. W., Dogan, A., Fisher, K., Goodman, A. M., Goyal, G., Guitart, J., Halwani, A., Haverkos, B. M., Hoppe, R. T., Jacobsen, E., Jagadeesh, D., Lunning, M. A., Mehta, A., Olsen, E. A., Pro, B., Rajguru, S. A., Shanbhag, S., Shaver, A., Shustov, A., Sokol, L., Torka, P., Torres-Cabala, C., Wilcox, R., William, B. M., Zain, J., Dwyer, M. A., Sundar, H., Kim, Y. H. 2020; 18 (5): 523–36Abstract
Mycosis fungoides (MF) is the most common subtype of cutaneous T-cell lymphoma (CTCL), and Sézary syndrome (SS) is a rare erythrodermic and leukemic subtype of CTCL characterized by significant blood involvement. Although early-stage disease can be effectively treated predominantly with skin-directed therapies, systemic therapy is often necessary for the treatment of advanced-stage disease. Systemic therapy options have evolved in recent years with the approval of novel agents such as romidepsin, brentuximab vedotin, and mogamulizumab. These NCCN Guidelines Insights discuss the diagnosis and management of MF and SS (with a focus on systemic therapy).
View details for DOI 10.6004/jnccn.2020.0022
View details for Web of Science ID 000531161900007
View details for PubMedID 32380458